PSAP 2018 Book 2 (*Hematology/Immunology/Oncology*)
Total Available Hours: 20.0
BCPS test deadline: 11:59 p.m. (Central) on September 17, 2018.
ACPE test deadline: 11:59 p.m. (Central) on May 14, 2021.

Hematology I (Module 1) – Credit Hours: 4.5

Chapter: Factor Products

Learning Objectives

1. Distinguish between different clotting factor deficiencies and the available clotting factors.

2. Devise a dosing and monitoring plan for acute bleeding in the patient with a clotting factor deficiency.

3. Distinguish among reversal strategies for different anticoagulant agents.

4. Delineate the role of individual reversal agents in coagulopathy normalization, together with the risk profile and monitoring values for each agent.

Chapter: Thrombocytopenia

Learning Objectives

1. Design treatment for patients with newly diagnosed and refractory immune thrombocytopenia (ITP).

2. Evaluate response to ITP treatment, and detect toxicities associated with each therapy option.

3. Assess a patient, including laboratory findings, to determine the etiology and recommended treatment for thrombotic microangiopathy.

4. Evaluate drug-induced thrombocytopenia, and justify medication discontinuation and/or alternative treatments as necessary.

Immunology I (Module 2) – Credit Hours: 5.5

Chapter: Systemic Lupus Erythematosus Learning Objectives

1. Distinguish between systemic lupus erythematosus (SLE) and other rheumatologic conditions according to the American College of Rheumatology and the Systemic Lupus International Collaborating Clinics recommendations for a diagnosis of SLE.

2. Assess patient response to SLE treatment on the basis of various disease activity indexes.

3. Develop an initial patient-specific treatment plan for the patient with SLE using a multimodal approach that is based on the patient's clinical manifestations.

4. Evaluate appropriate treatment regimens for lupus nephritis on the basis of patient-specific clinical and laboratory values.

Chapter: Hematopoietic Stem Cell Transplantation Learning Objectives

1. Demonstrate an understanding of the different types of hematopoietic cell transplantation (HCT) and the differences between conditioning intensity, donor sources, and graft sources.

- 2. Assess the indications for HCT for various hematologic malignancies.
- 3. Design a pharmacotherapy care plan for the most common complications in HCT recipients.
- 4. Devise an appropriate maintenance strategy for patients after HCT.

Oncology I (Module 3) – Credit Hours: 5.0

Chapter: New Therapies for Advanced NSCLC Learning Objectives

1. Distinguish the importance of histologic and genetic findings in determining the treatment subgroup for patients with newly diagnosed advanced-stage non-small cell lung cancer.

2. Select treatment for a patient on the basis of patient-specific histologic and genetic findings, and evaluate efficacy.

3. Demonstrate the ability to differentiate between immunotherapy response and toxicity compared with traditional cytotoxic chemotherapy treatment.

4. Recognize toxicities associated with targeted therapies, and design a preventive and/or management plan.

Chapter: Breast Cancer

Learning Objectives

1. Devise a treatment plan for a patient with a diagnosis of early-stage breast cancer.

2. Design appropriate therapy for a patient with a diagnosis of locally advanced positive breast cancer.

3. Given certain patient characteristics, develop a treatment plan for metastatic breast cancer.

4. Justify the role of bisphosphonates and bone-modifying agents in the treatment of breast cancer.

5. Develop a therapeutic plan for a patient with a diagnosis of triple-negative breast cancer.

6. Manage adverse events associated with newly approved breast cancer therapy.

Oncology II (Module 4) – Credit Hours: 5.0

Chapter: Skin Cancer

Learning Objectives

1. Assess the risk factors associated with developing melanoma from a patient history.

2. Develop an adjuvant treatment plan for a patient with melanoma.

3. Distinguish between the various immunotherapies and their place in the treatment of melanoma.

4. Develop a pharmacotherapeutic plan for managing immunotherapy-mediated adverse effects.

5. Design a treatment plan for a patient with nonmelanoma skin cancer.

Chapter: Cancer Clinical Trials

Learning Objectives

1. Distinguish between the different types of clinical trials.

2. Analyze the appropriateness of clinical trial end points.

- 3. Evaluate the advantages and disadvantages of various clinical trial designs.
- 4. Discuss potential barriers for participation in oncology clinical trials.
- 5. Assess the challenges of clinical trial designs in oncology.